GE HealthCare and Stanford Medicine Renew Research Collaboration to Advance Total Body PET/CT Technology

What You Should Know: 

– GE HealthCare has renewed its research collaboration with Stanford Medicine. A key intention of this renewed effort is the development and research of innovative total body PET/CT technology, aiming to explore new clinical pathways and enhance patient outcomes through advanced imaging solutions.

– The collaboration brings together the engineering expertise of GE HealthCare with the clinical and research leadership of Stanford Medicine to push the boundaries of what is possible in molecular imaging.

A Tool to Redefine Research and Patient Experience

This initiative is part of GE HealthCare’s broader effort to collaborate with leading healthcare institutions to demonstrate how total body PET/CT imaging can overcome barriers that have previously hindered its widespread adoption beyond oncology. Researchers at Stanford Medicine and engineers at GE HealthCare aim to advance a next-generation PET/CT system designed to provide new opportunities to improve diagnosis, staging, and therapeutic planning. The high sensitivity and spatial resolution of the technology are expected to create significant clinical advantages.

Molecular imaging with PET/CT offers opportunities for precision care across various disease states, including:

• Supporting theranostics in oncology for advanced prostate cancer treatment.
• Aiding in beta-amyloid imaging for Alzheimer’s evaluation.
• Assisting in myocardial perfusion evaluation for diagnosing coronary artery disease.

“This technology is designed to offer a level of sensitivity and spatial resolution that can change how we design and conduct molecular imaging studies,” adds Dr. Andrei Iagaru, Division Chief of Nuclear Medicine and Molecular Imaging, Stanford Medicine. “For example, such technological characteristics can create opportunities to reduce anesthesia use in pediatric imaging by dramatically shortening scan times and enable the exploration of dual-tracer studies and early diagnosis with far greater precision.”